The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.

The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.

The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share,  noting their strong positions in non-oncology markets and recent moves into cancer testing.

The effort, called SepTech, will begin on Sept. 1 and run through August 2029, and it picks up from an earlier project called ...

At AACR, HER2-targeted therapies showed promise in early-stage patients with breast and rectal cancers, as researchers pondered how to use ctDNA monitoring for greater personalization.

The firm plans to study the PI3K/AKT/mTOR inhibitor paxalisib in combination with Merck's Keytruda in microsatellite stable and proficient mismatch repair colorectal cancer.

New products for the week of Aug. 31, 2026: BillionToOne, Mirxes, OGT, and Eclipse Bioinnovations.

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

Transcriptomic and metabolomic analyses of blood samples collected over eight years identified population-level patterns and variable individual trajectories.

The proteomics firm has not yet priced the offering, and plans to list its shares on the Nasdaq Global Market under the ticker symbol ALMR.

STRIPE (Sequencing Targeted RNAs Identifies Pathogenic Events) complements TEQUILA-seq in enabling cost-effective and scalable analysis of full-length RNA molecules.

Last week, GenomeWeb’s readers were most interested in learning about a new report suggesting manipulation of antibody validation images is widespread among providers.